Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine
JOURNAL OF RHEUMATOLOGY, cilt.38, sa.3, ss.516-518, 2011 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 38 Sayı: 3
- Basım Tarihi: 2011
- Doi Numarası: 10.3899/jrheum.100718
- Dergi Adı: JOURNAL OF RHEUMATOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.516-518
- Anahtar Kelimeler: FAMILIAL MEDITERRANEAN FEV, ANAKINRA, RESISTANT, ETANERCEPT, ANAKINRA, CHILDREN, PROTEIN, PYRIN
- İstanbul Üniversitesi Adresli: Hayır
Özet
Objective. Familial Mediterranean fever (FMF) is a recessively inherited autoinflammatory disorder characterized by recurrent attacks of fever and serositis. Although colchicine is the standard therapy for preventing attacks and suppressing inflammation, 5%-10% of compliant patients are colchicine-resistant. We report the effect of anti-tumor necrosis factor therapy (etanercept) and anti-interleukin 1 (IL-1) treatment (anakinra) in 6 cases resistant to colchicine therapy.